Hodgkin Lymphoma News and Research

RSS

Distinct changes found in cancer and non-cancer immune cells in Waldenstrom macroglobulinemia

A new study by researchers at Winship Cancer Institute of Emory University finds that cancer-associated mutations originate in blood progenitor cells, leading to distinct changes in both cancer and non-cancer immune cells in Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma and its precursor IgM monoclonal gammopathy of undetermined significance (MGUS).

2 Sep 2021

Modified R-CODOX-M/IVAC regimen shows promise for treating sporadic Burkitt lymphoma

Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) that comes in three different variants: endemic, immunodeficiency-associated, and sporadic. Of these variants, sporadic BL is most commonly found outside malaria-endemic countries and typically seen in young adults.

1 Sep 2021

Adolescent and young adult cancer patients found to be well represented in NCI-sponsored clinical trials

Adolescent and young adult (AYA) patients with cancer have not seen the same improvements in survival over the years as their pediatric and older adult counterparts.

10 Aug 2021

Study may help refocus research efforts on adolescent and young adult cancer survivorship

Survival rates for adolescents and young adults diagnosed with cancer have varied considerably depending on cancer type.

26 Jul 2021

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.

23 Jul 2021

COVID-19 vaccines are effective in 94% of cancer patients, shows study

In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.

1 Jul 2021

RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors

Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects.

30 Jun 2021

New research uncovers substantial differences in rates of childhood cancers

New research uncovers substantial differences in rates of childhood cancers when considering single year of age rather than grouping several years together.

21 Jun 2021

NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells

Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center.

13 May 2021

Cognitive outcomes in survivors of childhood cancers have been largely understudied

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

23 Apr 2021

Race, neighborhood poverty, insurance associated with higher mortality in people under 40 with cancer

Being Black or Hispanic, living in high-poverty neighborhoods, and having Medicaid or no insurance coverage are associated with higher mortality in men and women under 40 with cancer, a review by UT Southwestern Medical Center researchers found.

22 Apr 2021

Researchers identify long-sought enzyme that prevents cancer

Researchers have found a long-sought enzyme that prevents cancer by enabling the breakdown of proteins that drive cell growth, and that causes cancer when disabled.

14 Apr 2021

Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma

Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.

8 Apr 2021

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

Collaborative teams that include Southwest Research Institute staff received two of six recently awarded San Antonio Medical Foundation (SAMF) bioscience grants. SwRI, in collaboration with UT Health San Antonio and University Health System, received a nearly $200,000 grant to develop machine learning algorithms for cancer detection.

31 Mar 2021

Underrepresentation in genomic databases may affect therapy selection for minority patients

Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.

19 Mar 2021

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

An innovative cell-based treatment for cancer has been found promising for the control of infections caused by fungi.

4 Mar 2021

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

$FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma$

FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma

Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

5 Feb 2021

Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients

Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

2 Feb 2021

FISH technique can be used to probe sperm DNA for chromosomal defects

Chemotherapy and radiation treatments are known to cause harsh side effects that patients can see or feel throughout their bodies.

19 Jan 2021